Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Odense University Hospital

Verified siteinfo

Denmark Kloevervaenget 6/3, 5000 Odense, Denmark

  • Bronchiectasis · Chronic obstructive pulmonary disease · Diffuse large B-cell lymphoma refractory
  • Adults and children

About Specializations

Odense University Hospital in Odense, Denmark specialises in clinical trials of conditions such as Bronchiectasis, Chronic obstructive pulmonary disease, Diffuse large B-cell lymphoma refractory, Endometrial cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms – Endometrial Cancer

At Odense University Hospital, investigators are evaluating a novel immunotherapy combined with standard post‑surgical treatment for women with high‑risk disease. The purpose is to improve long‑term outcomes by reducing cancer recurrence.

  • Disease‑free survival assessment
  • Overall survival measurement
  • Combination with adjuvant chemotherapy
  • Optional radiotherapy integration
  • Post‑surgical curative intent

The study seeks to determine whether adding the immune‑checkpoint inhibitor can extend both disease‑free and overall survival, offering a potential new standard of care for patients.

Respiratory Tract Diseases – Idiopathic Pulmonary Fibrosis

In a collaborative effort at Odense University Hospital, researchers are testing an inhaled therapy designed to target fibrotic pathways in the lungs. The trial focuses on safety and early signals of efficacy in a progressive lung condition.

  • Inhaled MMP7 inhibitor evaluation
  • Safety and tolerability monitoring
  • Pulmonary function testing
  • Biomarker profiling
  • Quality‑of‑life assessment

By exploring a localized treatment approach, the research hopes to slow disease progression and improve breathing capacity for patients with this challenging condition.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Kloevervaenget 6/35000 OdenseDenmark
Open in maps ↗
Recruiting now
no trials
Conditions studied
13
Partner status
Verified site

More sites in OdenseDenmark

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Condition
Type of trial
Recruitment status
Quick filters

12 clinical trials

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Diffuse large B-cell lymphoma refractory

Not yet recruiting

Study Comparing R-MINI-CHOP and R-MINI-CHP with Polatuzumab Vedotin for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older or Frail Patients Aged 75 and Older

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Region Skane

Insulin-requiring type 2 diabetes mellitus

Not recruiting

Study on Insulin Glargine for Patients with Type 2 Diabetes: Comparing Decentralized, Hybrid, and Standard Clinical Trial Approaches

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Universitair Medisch Centrum Utrecht

Chronic obstructive pulmonary disease

Not recruiting

Study on Benralizumab for Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with Frequent Exacerbations

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Type 2 diabetes mellitus

Not recruiting

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Plasma cell myeloma

Not recruiting

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Celgene Corp.

Follicular lymphoma+2

Not recruiting

Study of Mosunetuzumab for Patients with Early Relapse of Follicular Lymphoma

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:Oslo University Hospital HF

Non-small cell lung cancer metastatic

Not recruiting

Study on MK-7684A and Docetaxel for Treating Metastatic Non-Small Cell Lung Cancer in Patients After Platinum Chemotherapy and Immunotherapy

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effectiveness and Safety of Oral Azacitidine for Patients with Low or Intermediate-Risk Myelodysplastic Syndrome

Not recruiting
Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Celgene Corp.

Focal segmental glomerulosclerosis

Not recruiting

Study on the Effectiveness and Safety of DMX-200 with Losartan in Adults with Focal Segmental Glomerulosclerosis

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil
  • Sponsor:Dimerix Bioscience Pty Limited

Endometrial cancer

Not recruiting

Study of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Bronchiectasis

Not recruiting

Study on Long-Term Safety and Efficacy of BI 1291583 in Patients with Bronchiectasis

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.